Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
MIAMI, March 10, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported its financial results for the fourth quarter and full year of 2022.
- Financial Results for Fourth Quarter and Full Year Ended December 31, 2022 and 2021
Revenue: Revenue in the fourth quarter 2022 was $0.1 million compared to $0.2 million in the same period in 2021. - The difference was primarily due to a decrease in clinical trial revenue during the fourth quarter 2022.
- Selling & Marketing Expenses: Selling and marketing expenses in the fourth quarter of 2022 and 2021 were $0.3 million.
- ET to discuss the Company’s fourth quarter and full year 2022 financial results and provide a business update.